Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

328 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gender-sensitive reporting in medical research.
Heidari S, Abdool Karim Q, Auerbach JD, Buitendijk SE, Cahn P, Curno MJ, Hankins C, Katabira E, Kippax S, Marlink R, Marsh J, Marusic A, Nass HM, Montaner J, Pollitzer E, Ruiz-Cantero MT, Sherr L, Sow PS, Squires K, Wainberg MA. Heidari S, et al. Among authors: cahn p. J Int AIDS Soc. 2012 Mar 8;15(1):11. doi: 10.1186/1758-2652-15-11. J Int AIDS Soc. 2012. PMID: 22400977 Free PMC article.
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial.
Thompson M, Lalezari JP, Kaplan R, Pinedo Y, Pena OAS, Cahn P, Stock DA, Joshi SR, Hanna GJ, Lataillade M; AI438011 study team. Thompson M, et al. Among authors: cahn p. Antivir Ther. 2017;22(3):215-223. doi: 10.3851/IMP3112. Epub 2016 Dec 6. Antivir Ther. 2017. PMID: 27922453 Clinical Trial.
Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies.
Molina JM, Ene L, Cahn P, Fätkenheuer G, Van Wijngaerden E, Lombaard J, Zakharova N, Van Eygen V, Vanveggel S, Van Solingen-Ristea R. Molina JM, et al. Among authors: cahn p. Antivir Ther. 2021 Nov;26(6-8):95-105. doi: 10.1177/13596535211062388. Epub 2021 Nov 26. Antivir Ther. 2021. PMID: 35485339 Clinical Trial.
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, Wood R, Bloch M, Katlama C, Kastelein JJ, Schechter M, Murphy RL, Horban A, Hall DB, Lange JM, Reiss P. van Leth F, et al. Among authors: cahn p. PLoS Med. 2004 Oct;1(1):e19. doi: 10.1371/journal.pmed.0010019. Epub 2004 Oct 19. PLoS Med. 2004. PMID: 15526045 Free PMC article. Clinical Trial.
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration.
Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, Cane P, Clarke J, Sirivichayakul S, Soares MA, Snoeck J, Pillay C, Rudich H, Rodrigues R, Holguin A, Ariyoshi K, Bouzas MB, Cahn P, Sugiura W, Soriano V, Brigido LF, Grossman Z, Morris L, Vandamme AM, Tanuri A, Phanuphak P, Weber JN, Pillay D, Harrigan PR, Camacho R, Schapiro JM, Shafer RW. Kantor R, et al. Among authors: cahn p. PLoS Med. 2005 Apr;2(4):e112. doi: 10.1371/journal.pmed.0020112. Epub 2005 Apr 26. PLoS Med. 2005. PMID: 15839752 Free PMC article.
328 results